Use: Labeled indications
- Clobetasol Propionate Shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Clobetasol Propionate Shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older. (1) Limitations of Use: Do not use on the face, axillae or groin. (1.2) Avoid any contact with the eyes and lips. (1.2) 1.1 Indication Clobetasol Propionate Shampoo, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older.
Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Patients should be instructed to use Clobetasol Propionate Shampoo, 0.05%, for the minimum time period necessary to achieve the desired results [see Dosage and Administration (2)]. Use in patients younger than 18 years of age is not recommended due to numerically high rates of hypothalamic-pituitary-adrenal (HPA) axis suppression [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)]. 1.2 Limitations of Use Clobetasol Propionate Shampoo, 0.05%, should not be used on the face, groin or axillae.
Avoid any contact of the drug product with the eyes and lips. In case of contact, rinse thoroughly with water all parts of the body that came in contact with the shampoo.
Contraindications
4 CONTRAINDICATIONS None None (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Clobetasol Propionate Shampoo, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use. Clobetasol Propionate Shampoo, 0.05%, should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing.
The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Move the hair away from the scalp so that one of the affected areas is exposed. Position the bottle over the lesion. Apply a small amount of the shampoo directly onto the lesion, letting the product naturally flow from the bottle (gently squeeze the bottle), avoiding any contact of the product with the facial skin, eyes or lips.
In case of contact, rinse thoroughly with water. Spread the product so that the entire lesion is covered with a thin uniform film. Massage gently into the lesion and repeat for additional lesion(s). Wash your hands after applying Clobetasol Propionate Shampoo, 0.5%. Leave the shampoo in place for 15 minutes, then add water, lather and rinse thoroughly all parts of the scalp and body that came in contact with the shampoo (e.g., hands, face, neck and shoulders).
Avoid contact with eyes and lips. Minimize contact to non-affected areas of the body. Although no additional shampoo is necessary to cleanse your hair, you may use a non-medicated shampoo if desired. Treatment should be limited to 4 consecutive weeks. As with other corticosteroids, therapy should be discontinued when control is achieved.
If complete disease control is not achieved after 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05%, treatment with a less potent topical steroid may be substituted. If no improvement is seen within 4 weeks, reassessment of the diagnosis may be necessary. Clobetasol Propionate Shampoo, 0.05%, should not be used with occlusive dressings (shower cap or bathing cap) unless directed by a physician.
Not for oral, ophthalmic, or intravaginal use. (2) Clobetasol Propionate Shampoo, 0.05% should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only,and left in place for 15 minutes before lathering and rinsing. Clobetasol Propionate Shampoo, 0.05% contains a super-high potent topical corticosteroid; therefore treatment should be limited to 4 weeks.
(2) As with other corticosteroids, therapy should be discontinued when control is achieved. (2) Total dosage should not exceed 50 g (50mL or 1.75 fl. oz.) per week. (2) Clobetasol Propionate Shampoo should not be used with a shower cap or bathing cap. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Use of Clobetasol Propionate Shampoo, 0.05%, in patients under 18 years old is not recommended due to potential for HPA axis suppression [see Warnings and Precautions (5.1)]. The effect of Clobetasol Propionate (Clobetasol propionate) Shampoo, 0.05%, on HPA axis suppression was evaluated in one trial in adolescents 12 to 17 years of age with moderate to severe scalp psoriasis with involvement of at least 25% of the scalp.
In this trial, 5 of 12 evaluable subjects developed suppression of their HPA axis following 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05%, applied once daily for 15 minutes to a dry scalp before lathering and rinsing. Only 1 of the 5 subjects who had suppression was tested for recovery of HPA axis, and this subject recovered after 2 weeks.
No studies have been performed in patients under the age of 12. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment.
Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. Therefore, use is not recommended in patients under the age of 18. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids.
Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of Clobetasol Propionate Shampoo, 0.05%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
Dosage forms
Philippines
- Cream: 0.5 mg/g, 500 mcg/g
- Topical cream: 15 mg per 30 g, 500 mcg/g, 500 mcg/mg
- Topical ointment: 500 mcg/g
- Ointment: 0.5 mg/g, 500 mcg/g
- ) ointment: 0.5 mg/g
- Shampoo: 500 mcg/g
- Solution for scalp application: 500 mcg/mL
- W/w) cream: 25 mg/g (0.05 %
Registered products in the Philippines
69 products registered with the Food and Drug Administration (FDA) Philippines list Clobetasol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products69
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ActivesolClobetasol Propionate | 500mcg/g (0.05% w/w) CreamAluminum Tube with Screw Cap x 10g (Box of 1's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Vape Distribution and DrugstoreImporter: Yung Shin (Philippines), Inc. | DRP-8032-02 | Apr 5, 2031 | |
CBCORTClobetasol Propionate | 500 mcg/ g (0.05% w/w) Topical OintmentPrinted Lami Tube x 5 g and 15 g (Box of 1's) | OTC | KLM Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-11945 | May 23, 2032 | |
CleovateClobetasol propionate | 500 mcg/g (0.05% w/w) CreamAluminum Collapsible Tube x 5 g, 10 g and 15 g (Box of 1's) | Rx | Curetech SkincareIndia | Eon Pharmatek Inc.Trader: Subira Pharmaceuticals Pvt. Ltd. | DR-XY46236 | Feb 1, 2028 | |
Clobe-SkyClobetasol Propionate | 0.5 mg/g (0.5% w/w) CreamAluminum Collapsible Tube x 5 g (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | Skymed Pharma DistributorImporter: Ambica International Corporation | DRP-2909-03 | Apr 30, 2030 | |
ClobenateClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum tube x 15 g and 5 g Box of 1's | Rx | Micro Labs LimitedIndia | UNILAB, Inc. | DR-XY30066 | Sep 29, 2029 | |
ClobesaphClobetasol Propionate | 500 mcg/g (0.05% w/w) CreamLaminated Plastic Tube 10 g, 25 g, & 30 g (Box of 1's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-17931 | Apr 13, 2031 | |
ClobetacareClobetasol Propionate | 0.5 mg/g (0.05% w/w) Cream15 g Aluminum Collapsible Tube (Box of 1's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15264-02 | Jun 4, 2029 | |
ClobetarineClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum Collapsible Tube x 10 g (Box of 1’s) | Rx | Yash Medicare Private LimitedIndia | Medcare PharmaceuticalsImporter: Aglobal Care, Inc.Trader: Antilla Lifesciences Pvt. Ltd. | DRP-12305-02 | Dec 20, 2029 | |
ClobetorClobetasol Propionate | 500 mcg/g Cream15 g, 30 g, 45 g and 60 g Aluminum Collapsible Tube (Box of 1's) | Rx | Torrent Pharmaceuticals LimitedIndia | Torrent Pharma Philippines, Inc. | DR-XY48755 | May 30, 2028 | |
ClobetorClobetasol propionate | 500 mcg/g OintmentCollapsible aluminum tube with cap x 15 g, 30 g, 45 g, 60 g (Box of 1 tube x 15g; Box of 1 x 30g; Box of 1 tube x 45 g; Box of 1 tube x 45 g; Box of tube x 60g) | Rx | Torrent Pharmaceuticals LimitedIndia | Torrent Pharma Philippines Inc. | DR-XY48711 | Apr 26, 2028 | |
ClobewellClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum Collapsible Tube x 15 g (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Davao Point Pharmaceutical ProductsImporter: Wellchem Pharmaceutical Products | DRP-11531-01 | Mar 2, 2027 | |
ClobexClobetasol Propionate | 500 mcg/g (0.05% w/w) ShampooHDPE Bottle x 60 mL (Box of 1's) HDPE Bottle x 125 mL (Box of 1's) | Rx | Laboratories GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY32723 | Feb 17, 2028 | |
ClobfredClobetasol Propionate | 500mcg/g (0.05% w/w) OintmentLaminated Tube x 10 g and 15 g | OTC | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-11731 | Apr 25, 2027 | |
ClobilaClobetasol Propionate | 500 mcg/g (0.05 % w/w) Topical CreamAluminum Collapsible Tube x 10 g (Box of 1's) | Rx | Yash Medicare Private LimitedIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-12305 | Dec 20, 2029 | |
ClobimedClobetasol (as propionate) | 0.05% (0.5 mg/g) OintmentAluminum collapsible tube of 15g (Box of 1's) | Rx | Unijules Life Sciences LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4364-04 | Apr 8, 2028 | |
ClobphilClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical OintmentPrinted Lami Tube x 15g (Box of 1's) | OTC | KLM Laboratories Pvt. Ltd.India | Philrx Pharma Inc. | DRP-11945-02 | May 23, 2027 | |
ClofinaClobetasol Propionate | 500mcg/mg (0.05% w/w) Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Lincoln Pharmaceuticals Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-15431-02 | Jul 8, 2029 | |
ClohabClobetasol Propionate | 500 mcg/g (0.05% w/w) Ointment15 g Aluminum tube and PP cap (Box of l’s) | Rx | Kolmar Korea Co., Ltd.Korea | H&B Pharma International Inc. | DRP-11571 | Mar 30, 2027 | |
ClosdermClobetasol Propionate | 500mcg/g (0.05% w/w) CreamAluminum Tube with Screw Cap x 10g (Box of 1's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DRP-8032 | Apr 5, 2031 | |
ClovateClobetasol (as propionate) | 0.05% (0.5 mg/g) OintmentAluminum collapsible tube of 15g (Box of 1's) | Rx | Unijules Life Sciences LimitedIndia | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4364 | Apr 8, 2028 | |
ClovateClobetasol Propionate. | 0.5 mg/g (0.05% w/w) Cream15 g Aluminum Collapsible Tube [Box of 1's] le Tube [Box of 1's] | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International Corporation.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15264 . | Jun 4, 2029 | |
ClovateClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentAluminum collapsible tube x 15 g (Box of 1's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15273 | Jun 4, 2029 | |
ClubClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentLaminated Tube x 15 g (Box of 1's) | Rx | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-13710 | Mar 30, 2028 | |
CutisolClobetasol propionate | 500mcg/g (0.05 % w/w) Topical CreamAluminum Collapsible Tube x 5 g (Box of 1's) | Rx | Global Pharmaceuticals (Pvt) Ltd.Pakistan | Surestep Pharmaceuticals, Inc. | DR-XY49668 | Mar 11, 2031 | |
DermabetasolClobetasol (as propionate) | 0.05% (0.5 mg/g) OintmentAluminum collapsible tube x 15g (Box of 1's) | Rx | Unijules Life Sciences LimitedIndia | F.C. Andres Drug DistributorImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4364-02 | Apr 8, 2028 | |
DermabetasolClobetasol Propionate | 0.5 mg/g (0.05% w/w) Cream15 g Aluminum Collapsible Tube (Box of 1's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15264-01 | Jun 4, 2029 | |
DermafinaClobetasol propionate | 500 mcg/mg (0.05% w/w) Topical CreamAluminum Collapsible Tube x 15g (Box of 1's) | Rx | Lincoln Pharmaceuticals Ltd.India | Despina Pharma Inc. | DRP-15431 | Jul 8, 2029 | |
DermochemClobetasol Propionate | 500 mcg/g (0.05 % w/w) Topical CreamAluminum Collapsible Tube x 15 g (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Wellchem Pharmaceutical Products | DRP-11531 | Mar 2, 2027 | |
DermovateClobetasol Propionate | 500 mcg/g Cream5 g Aluminum Tube (Box of 1's) | Rx | GlaxoSmithKline Pharmaceuticals S.A.Poland | GlaxoSmithKline Philippines, Inc. | DR-10074 | Jan 18, 2028 | |
DermovateClobetasol Propionate | 500 mcg/g OintmentAluminum tube x 5 g (Box of 1's) | Rx | GlaxoSmithKline Pharmaceuticals S.A.Poland | GlaxoSmithKline Philippines, Inc. | DR-10073 | Jun 15, 2028 | |
DermovateClobetasol Propionate | 500 mcg/mL Solution for Scalp ApplicationPlastic bottle x 25 mL (Box of 1's) | Rx | Aspen Bad Oldesloe GmbHGermany | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY8271 | Jul 29, 2027 | |
DermovidClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentLaminated Tube x 7 g (Box of 1's) | Rx | Winston Medical Supply Co., Ltd.Taiwan | Hovid Inc.Trader: Hovid Bhd. | DRP-17794 | Mar 11, 2031 | |
EasekinClobetasol Propionate | 25 mg/g (0.05%w/w) CreamAluminum Collapsible Tube x 50 g (Box of 1's) | Rx | Synmedic LaboratoriesIndia | Ambica International Corporation | DRP 14370 | Jan 26, 2029 | |
EcmetrixClobetasol (As Propionate) | 500 mcg/g CreamLaminated HDPE/LDPE Plastic Tube with White Opaque Flip-top Cap and aluminum Seal x 30 g and 10 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-13217 | Jan 3, 2028 | |
EcmetrixClobetasol Propionate | 500 mcg/g Topical OintmentLaminated HDPE/LDPE plastic tube with white opaque flip-top cap and aluminum seal x 30 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-13220 | Jan 3, 2028 | |
EurobelClobetasol Propionate | 500 mcg/g Cream (0.05% w/w)Aluminum Tube x 10 g (Box of 1's) | Rx | Beximco Pharmaceuticals LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-1555 | Jan 29, 2029 | |
ForticrepClobetasol propionate | 500 mcg/g (0.05% w/w) Topical CreamLaminated Tube x 10g and 30g (Box of 1's) | Rx | Helios Pharmaceuticals (Division of P.K.T.P. Private Limited)India | Suhitas Pharmaceuticals, Inc.Trader: Mac Heal Laboratories Ltd. Comple | DRP-14922 | Feb 13, 2029 | |
GlevateClobetasol propionate | 500 mcg/g (0.05% w/w) CreamPrinted aluminum collapsible tube with white plastic cap x 5 g and 15 g; Printed aluminum collapsible tube with white plastic cap x 3 g (Physician's sample) | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-6216 | Mar 29, 2031 | |
GlevateClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical OintmentCollapsible Aluminum Tube Sealed with HDPE Fez Cap x 15g and 30g (Box of 1's) | Rx | Glenmark Pharmaceuticals LimitedIndia | Glenmark Philippines, Inc. | DRP-14460 | Sep 7, 2028 | |
Healthcare DermsolClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum Tube x 15 mg (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY39242 (For Export Only) | Mar 30, 2031 | |
KhrizvateClobetasol Propionate | 15mg per 30g (0.05% w/w) Topical CreamLaminated tube x 5g,10g,15g,20g,25g, and 30g (box of 1's) | OTC | Merit Organics Ltd.India | Khriz Pharma Trading Inc. | DRP-12493 | Aug 26, 2027 | |
LuixolClobetasol Propionate | 0.5mg/g (0.05% w/w) OintmentLaminated Aluminum Collapsible Tube x 10g (Box of 1's) | Rx | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DR-XY44708 | Jul 14, 2031 | |
MaxcortClobetasol (as propionate) | 0.05% w/w CreamLaminated Plastic Tube 5g & 15g (Box of 1's) | OTC | Yash PharmaceuticalsIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DRP-48716 | May 19, 2028 | |
NiosolClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentLaminated Collapsible Tube x 5 g and 15 g (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-9696 | May 5, 2031 | |
NoneClobetasol (as propionate) | 0.05% (0.5 mg/g) OintmentAluminum collapsible tube x 15g (Box of 1's) | Rx | Unijules Life Sciences LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4364-01 | Apr 8, 2028 | |
NoneClobetasol (as propionate) | 0.05% (0.5 mg/g) OintmentAluminum collapsible tube of 15g (Box of 1's) | Rx | Unijules Life Sciences LimitedIndia | Actimed, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4364-03 | Apr 8, 2028 | |
NoneClobetasol Propionate | 0.5 mg/g (0.05% w/w) CreamAluminum Collapsible Tube x 5 g and 15 g Box of 1’s | Rx | Agio Pharmaceuticals Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-2909 | Apr 30, 2030 | |
NoneClobetasol Propionate | 0.5 mg/g (0.5% w/w) CreamAluminum Collapsible Tube x 5 g Box of 1’s | Rx | Agio Pharmaceuticals Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2909-02 | Apr 30, 2030 | |
NoneClobetasol Propionate | 0.5 mg/g (0.5% w/w) CreamAluminum Collapsible Tube x 5 g Box of 1’s | Rx | Agio Pharmaceuticals Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-2909-04 | Apr 30, 2030 | |
NoneClobetasol propionate | 0.5mg/g (0.05% w/w) CreamPrinted aluminum collapsible tube with white plastic cap x 5g (Box of 1's) | Rx | Glenmark Pharmaceuticals Ltd.India | Watsons Personal Care Stores (Philippines) Inc.Importer: Glenmark Philippines, Inc. | DRP-6216-01 | Mar 29, 2031 | |
NoneClobetasol Propionate | 500 mcg / g (0.05% w/w) CreamPolypropylene White Jar 15 g x 1's (Box of 1's) | Rx | DS Cosmeceutical Manufacturing LaboratoryPhilippines | — | DRP-15233 | Nov 25, 2026 | |
NoneClobetasol propionate | 500 mcg/g (0.05% w/w) Topical CreamLaminated Tube x 10g and 30g (Box of 1’s) | Rx | Helios Pharmaceuticals (Division of P.K.T.P. Private Limited)India | Reta DrugImporter: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-14922-01 | Feb 13, 2029 | |
NoneClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical OintmentPrinted Lami Tube x 15 g (Box of 1's) | OTC | KLM Laboratories Pvt. Ltd.India | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-11945-01 | May 23, 2027 | |
NoneClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentAluminum collapsible tube x 15 g (Box of 1's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15273-02 | Jun 4, 2029 | |
ProbelinClobetasol Propionate | 500 mcg/g (0.05% w/w) CreamAluminum Tube x 10 g (Box of 1's) | Rx | Beximco Pharmaceuticals LimitedBangladesh | RX EMPIRE INTERNATIONAL TRADING INC.Importer: Euro Generics International Philippines Inc. | DRP-1555-01 | Jan 29, 2029 | |
PsorovateClobetasol Propionate | 500 mcg/g (0.05% w/v) Topical OintmentPrinted Lami Tube x 15 g (Box of 1's) | OTC | KLM Laboratories Pvt. Ltd.India | Brady Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-11945-03 | May 23, 2027 | |
RetabetasolClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum Collapsible Tube X 10 g (Box of 1’s) | Rx | Yash Medicare Private LimitedIndia | Reta DrugImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-12305-01 | Dec 20, 2029 | |
RistacClobetasol propionate | 500 mcg/g (0.05% w/w) Topical OintmentLaminated Tube x 15 g (Box of 1's) | Rx | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-13709 | Mar 30, 2028 | |
S-ClobeClobetasol propionate | 500 mcg / g (0.05 % w/w) Topical OintmentAluminum collapsible tube x 15 g (Box of 1's) | Rx | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-15273-01 | Jun 4, 2029 | |
TegucortClobetasol Propionate | 500mcg/mg (0.05% w/w) Topical CreamAluminum Collapsible Tube x 15 g (Box of 1’s) | Rx | Lincoln Pharmaceuticals Ltd.India | Integu Philippines, Inc.Importer: Despina Pharma Inc. | DRP-15431-01 | Jul 8, 2029 | |
TimovateClobetasol Propionate | 500 mcg/g (0.05% w/w) Topical Cream10 g Collapsible Aluminum Tube (Box of 1's) | Rx | Front Pharmaceutical PLCChina | Hexagon Pharmaceuticals | DR-XY47475 | Nov 16, 2026Past listed date | |
UnbrandedClobetasol Propionate | 500 mcg/g (0.05% w/w) CreamAluminum Collapsible Tube x 10 g Not Applicable | Rx | MCB Dermatological ProductsPhilippines | — | DR-XY45675 | Nov 15, 2031 | |
UnbrandedClobetasol Propionate | 500mcg/g (0.05% w/w) Cream | Rx | DS Cosmeceutical Manufacturing. Laboratory | — | DR-XY43916 | Nov 25, 2026 | |
ZemaxinClobetasol propionate | 500 mcg / g Topical CreamAluminum collapsible tube (Box of 5 g, 10 g and 15 g) | Rx | LifeSquare Laboratories, Inc.Cavite | — | DRP-7849 | May 18, 2031 | |
ZobexClobetasol propionate | 500 mcg/g (0.05%) CreamAluminum Tube x l0 g (Box of 1's) | Rx | Biopharma Laboratories LimitedBangladesh | JF DRAF PHARMACEUTICALS CORPORATION | DRP-2554 | May 4, 2031 | |
ZobexClobetasol Propionate | 500 mcg/g (0.05%) OintmentAluminum Tube x 10 g (Box of 1's) | Rx | Biopharma Laboratories LimitedBangladesh | Importer: JF Draf Pharmaceuticals Corp. | DRP-2550 | May 4, 2031 | |
(no brand name)Clobetasol propionate | 500 mcg/g (0.05% w/w) CreamAluminum Collapsible Tube x 10g (Box of 1s) | Rx | Hersil S.A. Laboratories Industriales FarmaceuticosPeru | Importer: Buergli Pharma, Inc. | DRP-2613 | Sep 8, 2028 | |
(no brand name)Clobetasol propionate | 500 mcg/g (0.05% w/w) Topical CreamAluminum Collapsible Tube x 15 g (Box of 1's) | Rx | Agio Pharmaceuticals Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-13882 | May 11, 2028 | |
(no brand name)Clobetasol Propionate | 500 mcg/g (0.05%) OintmentCollapsible Aluminum Tube with plastic screw cap x 5 g (Box of s l's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: Unilab, Inc. | DRP-13783 | Apr 19, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Shampoo, 0.05%, w/w. Each gram of Clobetasol Propionate Shampoo, 0.05%, contains 0.5 mg of clobetasol propionate in a translucent, colorless to pale yellow viscous liquid. Shampoo, 0.05% (3)
Warnings/Precautions
- Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis at the lowest doses tested. (5.1)
- Cushing’s syndrome, hyperglycemia and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. (5.1)
- Systemic absorption may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. (5.1)
- Children may be more susceptible to systemic toxicity from use of topical corticosteroids. (5.1, 8.4)
- If irritation develops in the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, use of Clobetasol Propionate Shampoo should be discontinued until the infection has been adequately controlled. (5.3)
- Local adverse reactions with topical corticosteroids may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, including clobetasol propionate. These reactions include: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria. (5.4)
5.1 Effects on the Endocrine System
5.1 Effects on the Endocrine System Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at the lowest doses tested. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency.
This may occur during treatment or upon withdrawal of the topical corticosteroid. The effect of Clobetasol Propionate Shampoo, 0.05% on HPA axis suppression was evaluated in one trial in adolescents 12 to 17 years of age. In this trial, 5 of 12 evaluable subjects developed suppression of their HPA axis following 4 weeks of treatment with Clobetasol Propionate Shampoo, 0.05% applied once daily for 15 minutes to a dry scalp before lathering and rinsing.
Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.
An adrenocorticotropic hormone (ACTH) stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios [see Use in Specific Populations (8.4)].
5.2 Allergic Contact Dermatitis
5.2 Allergic Contact Dermatitis If irritation develops, Clobetasol Propionate Shampoo, 0.05%, should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed with patch testing.
5.3 Concomitant Skin Infections
5.3 Concomitant Skin Infections In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, use of Clobetasol Propionate Shampoo, 0.05%, should be discontinued until the infection has been adequately controlled.
5.4 Local Adverse Reactions with Topical Corticosteroids
5.4 Local Adverse Reactions with Topical Corticosteroids Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria.
Some local adverse reactions may be irreversible. Clobetasol propionate is not recommended in patients with acne vulgaris, rosacea or perioral dermatitis.
Adverse reactions
- The most common adverse reactions are burning/stinging, pruritus, edema, folliculitis, acne, dry skin, irritant dermatitis, alopecia, urticaria, skin atrophy and telangiectasia. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials with Clobetasol Propionate Shampoo, 0.05%, the following adverse reactions have been reported: headache, burning/stinging, pruritus, edema, folliculitis, acne, dry skin, irritant dermatitis, alopecia, urticaria, skin atrophy and telangiectasia.
Table 1 summarizes selected adverse reactions that occurred in at least 1% of subjects in the Phase 2 and 3 studies for scalp psoriasis. Table 1: Summary of Selected Averse Reactions ≥ 1% by Body System Body System Clobetasol Propionate Shampoo, 0.05% N=558 Vehicle Shampoo N=127 Skin and Appendages 49 (8.8%) 28 (22.0%) Discomfort Skin 26 (4.7%) 16 (12.6%) Pruritus 3 (0.5%) 9 (7.1%) Body as a Whole 33 (5.9%) 12 (9.4%) Headache 10 (1.8%) 1 (0.8%) Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-approval use of Clobetasol Propionate Shampoo, 0.05%.
Endocrine disorders: Cushing’s syndrome, Adrenal suppression Eye: Eye pain, Vision blurred, Eye irritation CNS: Dizziness GI: Nausea Skin: Erythema, Skin exfoliation, Rash, Skin irritation, Hair color changes, Allergic contact dermatitis, Pain of skin, Skin tightness Other: Psoriasis (aggravation)
Adverse reaction frequency tables (US label) US FDA label
| Body System | Clobetasol Propionate Shampoo, 0.05% N=558 | Vehicle Shampoo N=127 |
| Skin and Appendages | 49 (8.8%) | 28 (22.0%) |
| Discomfort Skin | 26 (4.7%) | 16 (12.6%) |
| Pruritus | 3 (0.5%) | 9 (7.1%) |
| Body as a Whole | 33 (5.9%) | 12 (9.4%) |
| Headache | 10 (1.8%) | 1 (0.8%) |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Teratogenic effects: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Therefore, Clobetasol Propionate Shampoo, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. Clobetasol propionate is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and the mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less potent.
The effect of clobetasol propionate on pregnancy outcome and development of offspring was studied in the rat. Clobetasol propionate was administered subcutaneously to female rats twice daily (0, 12.5, 25, and 50 µg/kg/day) from day 7 of presumed gestation through day 25 of lactation or day 24 presumed gestation for those rats that did not deliver a litter.
The maternal no-observed-effect-level (NOEL) for clobetasol propionate was less than 12.5 μg/kg/day due to reduced body weight gain and feed consumption during the gestation period. The reproductive NOEL in the dams was 25 μg/kg/day (ratio of animal dose to proposed human dose of 0.07 on a mg/m 2 /day basis) based on prolonged delivery at a higher dose level.
The no-observed-adverse-effect-level (NOAEL) for viability and growth in the offspring was 12.5 μg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m 2 /day basis) based on incidence of stillbirths, reductions in pup body weights on days 1 and 7 of lactation, increased pup mortality, increases in the incidence of umbilical hernia, and increases in the incidence of pups with cysts on the kidney at higher dose levels during the preweaning period. The weights of the epididymides and testes were significantly reduced at higher dosages.
Despite these changes, there were no effects on the mating and fertility of the offspring.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Clobetasol Propionate Shampoo, 0.05%, is administered to a nursing woman.
Mechanism of action
12.1 Mechanism of Action Like other topical corticosteroids, Clobetasol Propionate Shampoo, 0.05%, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins.
It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.3 Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier and occlusion. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and other disease processes in the skin may increase percutaneous absorption.
There are no human data regarding the distribution of corticosteroids to body organs following topical application. Nevertheless, once absorbed through the skin, topical corticosteroids are handled through metabolic pathways similar to systemically administered corticosteroids. They are metabolized, primarily in the liver, and are then excreted by the kidneys.
In addition, some corticosteroids and their metabolites are also excreted in the bile.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
12.2 Pharmacodynamics Vasoconstrictor Assay Clobetasol Propionate Shampoo, 0.05%, is in the super-high range of potency as demonstrated in vasoconstrictor studies in healthy subjects when compared with other topical corticosteroids. However, similar blanching scores do not necessarily imply therapeutic equivalence. Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression In studies evaluating the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression, use of Clobetasol Propionate Shampoo Shampoo, 0.05%, resulted in demonstrable HPA axis suppression in 5 out of 12 (42%) adolescent subjects [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Clobetasol Cream 0.05%, 5 g Tube | ₱48.32–₱145.00Reference ₱50.21 | per tube | DPRI procurement range |
| Clobetasol Ointment 0.05%, 5 g Tube | ₱48.32Reference ₱48.32 | per tube | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Clobetasol (as propionate) |
| PNF listing | Cream or Ointment: 0.05%, 5 g and 15 g tube |
| PNF listing | Shampoo: 0.05%, 25 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. clobetasol propionate · Mayne Pharma Inc. [US FDA-approved label, version 1, August 16, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=524397b3-84c4-49d7-af5e-bb229dfee68b
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .